Novartis
Swiss pharma giant — Kymriah CAR-T pioneer and Cosentyx antibody blockbuster; large-scale biologics manufacturing across Basel and US sites.
- Country
- Switzerland
- Revenue
- $52.7B
- Employees
- ~78,000 emp
GMP EU
FDA GMP
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| CAR-T cell therapy | therapeutics-platforms | Low | → |
| Corporate biotech accelerators (JLABS, Bayer CoLaborator) | finance-investment | Medium | → |
| Gene therapy | therapeutics-platforms | High | → |
| In-vivo gene therapy: AAV and lentiviral vectors | therapeutics-platforms | Medium | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
| Radiopharmaceuticals & theranostics | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.